Here's your in­vi­ta­tion to this year's End­points 11 awards. Let's cel­e­brate the best of biotech to­geth­er

Over in the pub­lic mar­ket, we’re watch­ing the wheat be­ing re­morse­less­ly sep­a­rat­ed from the chaff as the biotech sec­tor went from every­one’s dar­ling to the or­phan child of Wall Street. That was in­evitable. But while there’s been a knock-on ef­fect in the ven­ture in­vest­ing side, we’re see­ing clear ev­i­dence that big play­ers are stick­ing with their game plan: Ma­jor tech­no­log­i­cal break­throughs are open­ing doors to biotech star­tups that didn’t ex­ist five years ago — and the so­phis­ti­cat­ed in­vestors don’t want to miss out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER